News headlines about Merrimack Pharmaceuticals (NASDAQ:MACK) have trended somewhat positive on Wednesday, according to Accern Sentiment. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.7069160899168 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of Merrimack Pharmaceuticals (NASDAQ MACK) traded up $0.25 during trading on Wednesday, hitting $10.90. The stock had a trading volume of 158,813 shares, compared to its average volume of 175,419. The company has a quick ratio of 3.35, a current ratio of 3.35 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $145.33, a P/E ratio of -1.50 and a beta of 1.72. Merrimack Pharmaceuticals has a 12 month low of $10.04 and a 12 month high of $48.60.

Several analysts have recently weighed in on the company. Robert W. Baird restated a “hold” rating and set a $15.00 target price on shares of Merrimack Pharmaceuticals in a research note on Friday, October 13th. ValuEngine upgraded Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. Finally, Zacks Investment Research downgraded Merrimack Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Merrimack Pharmaceuticals (MACK) Stock Price” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-merrimack-pharmaceuticals-mack-stock-price/1793211.html.

About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.

Insider Buying and Selling by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.